Deciphera Pharmaceuticals Inc is a United States-based company. The Company is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. Its switch-control kinase inhibitor platform and applies research and development in kinase biology. The Company design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines through patient-inspired approach.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Market Closed - Nasdaq 01:30:00 11/06/2024 am IST			5-day change	1st Jan Change
25.59 ^USD	+0.08%		-.--%	-

17/06	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
26/03	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI

Market Cap	221.29Cr 189.47Cr 176.78Cr 162.21Cr 304.81Cr 21TCr 310.8Cr 2.1TCr 817.52Cr 11TCr 830.91Cr 812.83Cr 35TCr	P/E 2022	-6.92x	P/E 2023	-7.04x
Enterprise Value	188.59Cr 161.47Cr 150.65Cr 138.24Cr 259.76Cr 18TCr 264.87Cr 1.79TCr 696.7Cr 9.04TCr 708.11Cr 692.7Cr 30TCr	EV / Sales 2022	59,51,009x	EV / Sales 2023	59,09,487x
Free-Float	71.62%	Yield 2022 *	-	Yield 2023	-

17/06	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
26/03	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI
17/02	Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL	CI
06/12	Deciphera Pharmaceuticals Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemiaera at the 67th American Society of Hematology Annual Meeting	CI
28/25/28	Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza?? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor	CI
15/25/15	Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Approval of Deciphera's Romvimza?? for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor	CI
11/24/11	Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	DJ
11/24/11	Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
11/24/11	Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion	MT
11/24/11	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index	CI
11/24/11	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index	CI
11/24/11	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index	CI
11/24/11	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index	CI

30/24/30	Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	MT
30/24/30	Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	MT
30/24/30	JMP Downgrades Deciphera Pharmaceuticals to Market Perform	MT
29/24/29	JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	MT
29/24/29	Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	MT

Deciphera Pharmaceuticals, Inc. Share Price

Stocks

DCPH

US24344T1016

Biotechnology & Medical Research

Valuation: Deciphera Pharmaceuticals, Inc.

Latest news : Deciphera Pharmaceuticals, Inc.

Analysts' recommendations: Deciphera Pharmaceuticals, Inc.

Press Releases: Deciphera Pharmaceuticals, Inc.

News in other languages: Deciphera Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Deciphera Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

03/24/03	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	BU
02/24/02	DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH	BU
29/24/29	Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	BU
09/24/09	Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	BU
27/24/27	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	BU

14/22/14	En los barrios más pobres de Cuba, jóvenes podrían enfrentar décadas de cárcel tras las protestas
30/21/30	Barbados renuncia a la reina de Inglaterra para convertirse en una república

Manager	Title	Age	Since
Ryota Udagawa CEO	Chief Executive Officer	-	01/11/2024
Rodrigo Ruiz Soto CTO	Chief Tech/Sci/R&D Officer	-	01/01/2017
Dashyant Dhanak CTO	Chief Tech/Sci/R&D Officer	63	05/09/2023

Director	Title	Age	Since
Toichi Takino BRD	Director/Board Member	57	11/06/2024
Masayuki Tanigawa BRD	Director/Board Member	-	11/06/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/06/24	Jama Pitman	Free	Executive/Senior Manager	3,23,737	0.3744%
11/06/24	Dashyant Dhanak	Free	Chief Technology Officer	3,45,001	0.3990%
11/06/24	Steven Hoerter	Free	Chief Executive Officer	22,74,105	2.6298%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DECIPHERA PHARMACEUTICALS, INC.	+0.08%	-.--%	-.--%	+75.15%	221.29Cr
WUXI APPTEC CO., LTD.	+2.38%	+3.43%	+82.88%	+115.89%	7.22TCr
ARGENX SE	+0.87%	+17.34%	+57.17%	+97.28%	6.4TCr
INSMED INCORPORATED	-4.27%	-0.99%	-3.38%	+475.61%	2.85TCr
BIONTECH SE	-1.97%	+20.38%	-0.37%	+0.48%	2.84TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.53%	+11.65%	+60.92%	+26.63%	2.51TCr
GENMAB A/S	-0.51%	+5.73%	+38.71%	-12.79%	2TCr
PHARMAESSENTIA CORPORATION	-1.79%	-4.84%	+239.54%	+414.48%	1.82TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.78%	+4.23%	+19.55%	+538.24%	1.6TCr
EXELIXIS, INC.	-1.29%	+6.09%	+41.81%	+154.45%	1.35TCr
Average	-0.32%	+4.94%	+53.68%	+188.54%	2.88TCr
Weighted average by Cap.	+0.20%	+7.64%	+59.26%	+163.03%

	2022	2023
Net sales	134.04 114.76 107.07 98.25 184.62 12.83T 188.25 1.27T 495.17 6.43T 503.28 492.33 21.28T	163.36 139.87 130.5 119.74 225 15.63T 229.43 1.55T 603.49 7.83T 613.37 600.02 25.93T
Net income	-18Cr -15Cr -14Cr -13Cr -25Cr -1.71TCr -25Cr -169.57Cr -66Cr -858.03Cr -67Cr -66Cr -2.84TCr	-19Cr -17Cr -16Cr -14Cr -27Cr -1.87TCr -27Cr -184.74Cr -72Cr -934.81Cr -73Cr -72Cr -3.09TCr
Net Debt	-31Cr -27Cr -25Cr -23Cr -43Cr -2.97TCr -44Cr -293.71Cr -114.49Cr -1.49TCr -116.37Cr -113.84Cr -4.92TCr	-33Cr -28Cr -26Cr -24Cr -45Cr -3.13TCr -46Cr -309.93Cr -120.82Cr -1.57TCr -122.8Cr -120.12Cr -5.19TCr

3 years	9.9	25.61
5 years	6.51	37.99
10 years	6.51	71.11